These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

3961 related items for PubMed ID: 6354414

  • 1. Intensive 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU), NSC #4366650 and cryopreserved autologous marrow transplantation for refractory cancer. A phase I-II study.
    Phillips GL, Fay JW, Herzig GP, Herzig RH, Weiner RS, Wolff SN, Lazarus HM, Karanes C, Ross WE, Kramer BS.
    Cancer; 1983 Nov 15; 52(10):1792-802. PubMed ID: 6354414
    [Abstract] [Full Text] [Related]

  • 2. Intensive 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU) monochemotherapy and autologous marrow transplantation for malignant glioma.
    Phillips GL, Wolff SN, Fay JW, Herzig RH, Lazarus HM, Schold C, Herzig GP.
    J Clin Oncol; 1986 May 15; 4(5):639-45. PubMed ID: 3009725
    [Abstract] [Full Text] [Related]

  • 3. High-dose carmustine, thiotepa and etoposide followed by autologous bone marrow rescue for the treatment of high risk central nervous system tumors.
    Papadakis V, Dunkel IJ, Cramer LD, Kramer E, Papadopoulos E, Goldman S, Packer RJ, Willoughby M, Baker D, Garvin J, Strandjord S, Coccia P, Kaplan AM, Klemperer M, Finlay JL.
    Bone Marrow Transplant; 2000 Jul 15; 26(2):153-60. PubMed ID: 10918425
    [Abstract] [Full Text] [Related]

  • 4. Autologous bone-marrow transplantation: host effects of high-dose BCNU.
    Takvorian T, Parker LM, Hochberg FH, Canellos GP.
    J Clin Oncol; 1983 Oct 15; 1(10):610-20. PubMed ID: 6366127
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Prolongation of survival for high-grade malignant gliomas with adjuvant high-dose BCNU and autologous bone marrow transplantation.
    Johnson DB, Thompson JM, Corwin JA, Mosley KR, Smith MT, de los Reyes RA, Daly MB, Petty AM, Lamaster D, Pierson WP.
    J Clin Oncol; 1987 May 15; 5(5):783-9. PubMed ID: 3553437
    [Abstract] [Full Text] [Related]

  • 10. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study.
    Wheeler C, Antin JH, Churchill WH, Come SE, Smith BR, Bubley GJ, Rosenthal DS, Rappaport JM, Ault KA, Schnipper LE.
    J Clin Oncol; 1990 Apr 15; 8(4):648-56. PubMed ID: 2313334
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Phase I-II study of two consecutive courses of high-dose epipodophyllotoxin, ifosfamide, and carboplatin with autologous bone marrow transplantation for treatment of adult patients with solid tumors.
    Lotz JP, Machover D, Malassagne B, Hingh B, Donsimoni R, Gumus Y, Gerota J, Lam Y, Tulliez M, Marsiglia H.
    J Clin Oncol; 1991 Oct 15; 9(10):1860-70. PubMed ID: 1919636
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pulmonary toxicity following carmustine-based preparative regimens and autologous peripheral blood progenitor cell transplantation in hematological malignancies.
    Alessandrino EP, Bernasconi P, Colombo A, Caldera D, Martinelli G, Vitulo P, Malcovati L, Nascimbene C, Varettoni M, Volpini E, Klersy C, Bernasconi C.
    Bone Marrow Transplant; 2000 Feb 15; 25(3):309-13. PubMed ID: 10673703
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. High-dose combination alkylating agent preparative regimen with autologous bone marrow support: the Dana-Farber Cancer Institute/Beth Israel Hospital experience.
    Antman K, Eder JP, Elias A, Shea T, Peters WP, Andersen J, Schryber S, Henner WD, Finberg R, Wilmore D.
    Cancer Treat Rep; 1987 Feb 15; 71(2):119-25. PubMed ID: 3542208
    [Abstract] [Full Text] [Related]

  • 17. Phase 1 trial of O6-benzylguanine and BCNU in children with CNS tumors: a Children's Oncology Group study.
    Adams DM, Zhou T, Berg SL, Bernstein M, Neville K, Blaney SM, Children's Oncology Group.
    Pediatr Blood Cancer; 2008 Mar 15; 50(3):549-53. PubMed ID: 17941066
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Acute lung injury following treatment with high-dose cyclophosphamide, cisplatin, and carmustine: pharmacodynamic evaluation of carmustine.
    Jones RB, Matthes S, Shpall EJ, Fisher JH, Stemmer SM, Dufton C, Stephens JK, Bearman SI.
    J Natl Cancer Inst; 1993 Apr 21; 85(8):640-7. PubMed ID: 8468721
    [Abstract] [Full Text] [Related]

  • 20. Phase II study of 1,3-bis (2-chloroethyl)-1-nitrosourea (BCNU, NSC No. 409962) with amphotericin B in bronchogenic carcinoma.
    Presant CA, Hillinger S, Klahr C.
    Cancer; 1980 Jan 01; 45(1):6-10. PubMed ID: 6243243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 199.